Free Trial

Arvinas (ARVN) Stock Price, News & Analysis

Arvinas logo
$6.69 +0.18 (+2.76%)
Closing price 04:00 PM Eastern
Extended Trading
$6.78 +0.09 (+1.35%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Arvinas Stock (NASDAQ:ARVN)

Key Stats

Today's Range
$6.48
$6.79
50-Day Range
$6.07
$9.62
52-Week Range
$5.90
$36.20
Volume
1.89 million shs
Average Volume
2.24 million shs
Market Capitalization
$488.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.92
Consensus Rating
Moderate Buy

Company Overview

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Arvinas Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

ARVN MarketRank™: 

Arvinas scored higher than 75% of companies evaluated by MarketBeat, and ranked 262nd out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 12 buy ratings, 8 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arvinas has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Arvinas' stock forecast and price target.
  • Earnings Growth

    Earnings for Arvinas are expected to grow in the coming year, from ($3.81) to ($3.68) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arvinas is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arvinas is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arvinas has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Arvinas' valuation and earnings.
  • Percentage of Shares Shorted

    10.14% of the outstanding shares of Arvinas have been sold short.
  • Short Interest Ratio / Days to Cover

    Arvinas has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Arvinas has recently decreased by 4.27%, indicating that investor sentiment is improving.
  • Dividend Yield

    Arvinas does not currently pay a dividend.

  • Dividend Growth

    Arvinas does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.14% of the outstanding shares of Arvinas have been sold short.
  • Short Interest Ratio / Days to Cover

    Arvinas has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Arvinas has recently decreased by 4.27%, indicating that investor sentiment is improving.
  • News Sentiment

    Arvinas has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Arvinas this week, compared to 6 articles on an average week.
  • Search Interest

    12 people have searched for ARVN on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $74,372.00 in company stock.

  • Percentage Held by Insiders

    Only 4.73% of the stock of Arvinas is held by insiders.

  • Percentage Held by Institutions

    95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arvinas' insider trading history.
Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Stock News Headlines

While others chase AI stocks, smart traders do this
Since the pandemic, the average mortgage payment has jumped from $1,427 to $2,047. That's an extra $600 every single month just vanishing from people's pockets. Meanwhile, credit card debt is hitting record highs, and savings accounts are at their lowest since 2008. Most folks are left with two options… Get a second job... or work overtime on weekends. But what if there was a third option? I just uncovered a shocking anomaly in the options market that could change everything... One that lets you target extra cash on days when most people make nothing - weekends. Think what that could mean for your monthly budget...
Arvinas Inc.
UBS Group Cuts Arvinas (NASDAQ:ARVN) Price Target to $21.00
See More Headlines

ARVN Stock Analysis - Frequently Asked Questions

Arvinas' stock was trading at $19.17 at the beginning of 2025. Since then, ARVN shares have decreased by 64.8% and is now trading at $6.7470.
View the best growth stocks for 2025 here
.

Arvinas, Inc. (NASDAQ:ARVN) released its quarterly earnings results on Thursday, May, 1st. The company reported $1.14 earnings per share for the quarter, beating the consensus estimate of ($0.93) by $2.07. The company's revenue for the quarter was up 646.2% on a year-over-year basis.
Read the conference call transcript
.

Arvinas (ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Top institutional investors of Arvinas include Vanguard Group Inc. (11.46%), Alyeska Investment Group L.P. (2.47%), Millennium Management LLC (1.80%) and Philosophy Capital Management LLC (1.36%). Insiders that own company stock include John G Houston, Sean A Cassidy, Ian Taylor, Noah Berkowitz, Ronald Peck and David K Loomis.
View institutional ownership trends
.

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arvinas investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/01/2025
Today
5/27/2025
Next Earnings (Estimated)
7/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
420
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.92
High Stock Price Target
$55.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+210.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
20 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-198,900,000.00
Pretax Margin
-75.29%

Debt

Sales & Book Value

Annual Sales
$426.90 million
Price / Cash Flow
N/A
Book Value
$8.17 per share
Price / Book
0.82

Miscellaneous

Free Float
65,175,000
Market Cap
$491.08 million
Optionable
Optionable
Beta
2.21
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:ARVN) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners